Regeneron Pharmaceuticals SG&A Expenses 2010-2024 | REGN

Regeneron Pharmaceuticals sg&a expenses for the twelve months ending September 30, 2024 were $2.900B, a 13.54% increase year-over-year.

  • Regeneron Pharmaceuticals annual sg&a expenses for 2023 were $2.631B, a 24.36% increase from 2022.
  • Regeneron Pharmaceuticals annual sg&a expenses for 2022 were $2.116B, a 15.95% increase from 2021.
  • Regeneron Pharmaceuticals annual sg&a expenses for 2021 were $1.825B, a 35.58% increase from 2020.

Regeneron Pharmaceuticals SG&A Expenses 2010-2024 | REGN

  • Regeneron Pharmaceuticals annual sg&a expenses for 2023 were $2.631B, a 24.36% increase from 2022.
  • Regeneron Pharmaceuticals annual sg&a expenses for 2022 were $2.116B, a 15.95% increase from 2021.
  • Regeneron Pharmaceuticals annual sg&a expenses for 2021 were $1.825B, a 35.58% increase from 2020.